• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

培美曲塞维持治疗对多原发性恶性肿瘤的长期生存作用

Prolonged survival with maintenance pemetrexed for a multiple primary malignancy.

作者信息

Shuayb Md, Reza Md Salim

机构信息

Square Oncology and Radiotherapy Centre, Square Hospitals, Dhaka, Bangladesh.

出版信息

BMJ Support Palliat Care. 2019 Mar;9(1):51-53. doi: 10.1136/bmjspcare-2018-001559. Epub 2018 May 18.

DOI:10.1136/bmjspcare-2018-001559
PMID:29776903
Abstract

Despite the fact that multiple primary malignancies (MPMs) are not new and have been diagnosed for about a hundred-year time, literatures on lung and colon primaries are scarce. We report a case of a 62-year-old Asian Bangladeshi man with stage IV lung adenocarcinoma who developed a metachronous stage II colon adenocarcinoma approximately 3 years later. A chemotherapy protocol of six cycles of pemetrexed/cisplatin followed by maintenance pemetrexed was used, and surgery was done for the colon primary. With more than 5 years of periodic follow-up, his disease remains stable without any local or metastatic recurrence. Definitive therapeutic protocols are unavailable, but information taken with caution from case reports may be of importance for treatment decisions of MPMs. We believe that management with careful judgement by a multidisciplinary team may result in a good outcome with longer survival.

摘要

尽管多原发性恶性肿瘤(MPMs)并非新鲜事物,且已被诊断约百年,但关于肺和结肠原发性肿瘤的文献却很稀少。我们报告一例62岁的亚洲孟加拉男性,患有IV期肺腺癌,约3年后出现异时性II期结肠腺癌。采用了培美曲塞/顺铂六个周期化疗方案,随后进行培美曲塞维持治疗,并对结肠原发性肿瘤进行了手术。经过5年多的定期随访,他的病情保持稳定,无任何局部或转移复发。目前尚无明确的治疗方案,但从病例报告中谨慎获取的信息可能对MPMs的治疗决策具有重要意义。我们认为,由多学科团队进行谨慎判断的管理可能会带来良好的结果和更长的生存期。

相似文献

1
Prolonged survival with maintenance pemetrexed for a multiple primary malignancy.培美曲塞维持治疗对多原发性恶性肿瘤的长期生存作用
BMJ Support Palliat Care. 2019 Mar;9(1):51-53. doi: 10.1136/bmjspcare-2018-001559. Epub 2018 May 18.
2
Use of pemetrexed for non-small cell lung cancer in the Andalusian public health system.培美曲塞在安达卢西亚公共卫生系统中用于非小细胞肺癌的情况。
J Chemother. 2015;27(6):371-7. doi: 10.1179/1973947815Y.0000000024. Epub 2015 May 14.
3
Unusually prolonged pemetrexed cytotoxicity in a patient with a lung adenocarcinoma: a case report.一名肺腺癌患者出现异常延长的培美曲塞细胞毒性:病例报告
J Med Case Rep. 2017 Sep 16;11(1):262. doi: 10.1186/s13256-017-1436-7.
4
[A case of Carboplatin and pemetrexed combination chemotherapy for synchronous double cancers of hepatocellular carcinoma and primary lung cancer].[卡铂与培美曲塞联合化疗治疗肝细胞癌和原发性肺癌同步双癌1例]
Gan To Kagaku Ryoho. 2014 Nov;41(12):2154-6.
5
FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer.18F-氟代脱氧葡萄糖正电子发射断层扫描在评估复发非小细胞肺癌患者对纳武单抗的反应中的应用
World J Surg Oncol. 2016 Sep 5;14(1):238. doi: 10.1186/s12957-016-0998-y.
6
Three-Year Follow-Up of a Randomized Phase II Trial on Refinement of Early-Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin and Vinorelbine (the TREAT Study).早期非小细胞肺癌辅助化疗中顺铂和培美曲塞与顺铂和长春瑞滨的精细调整的随机 II 期试验的 3 年随访结果(TREAT 研究)。
J Thorac Oncol. 2016 Jan;11(1):85-93. doi: 10.1016/j.jtho.2015.09.014.
7
Double cancer (lung and colon cancer) that showed complete remission with irinotecan and cisplatin combined chemotherapy.经伊立替康和顺铂联合化疗后完全缓解的双原发癌(肺癌和结肠癌)。
J Gastroenterol. 2000;35(11):864-9. doi: 10.1007/s005350070025.
8
Microwave ablation combined with chemotherapy improved progression free survival of IV stage lung adenocarcinoma patients compared with chemotherapy alone.微波消融联合化疗较单纯化疗改善 IV 期肺腺癌患者无进展生存期。
Thorac Cancer. 2019 Jul;10(7):1628-1635. doi: 10.1111/1759-7714.13129. Epub 2019 Jun 27.
9
Phase 2 trial of neoadjuvant bevacizumab plus pemetrexed and carboplatin in patients with unresectable stage III lung adenocarcinoma (GASTO 1001).不可切除 III 期肺腺癌患者新辅助贝伐珠单抗联合培美曲塞和顺铂的 II 期临床试验(GASTO 1001)。
Cancer. 2016 Mar 1;122(5):740-7. doi: 10.1002/cncr.29800. Epub 2015 Dec 23.
10
Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations.LUX-Lung 3 研究:阿法替尼或顺铂/培美曲塞治疗伴有 EGFR 突变的晚期肺腺癌患者的 III 期研究:症状控制和生活质量。
J Clin Oncol. 2013 Sep 20;31(27):3342-50. doi: 10.1200/JCO.2012.46.1764. Epub 2013 Jul 1.